SuperworthHemab Therapeutics EPS COAG
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.80
Hemab Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.80.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$0.80 | n/a | |
| Q1 FY26 | −$23.98 | n/a | |
| Q2 FY25 | −$12.91 | n/a | |
| Q1 FY25 | −$16.18 | n/a |
Against its peers
Companies in Biotechnology nearest Hemab Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| COAGHemab Therapeutics | n/m | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| MGTXMeiraGTx | $0.71 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| Peer median | $0.94 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Hemab Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.